Equity Overview
Price & Market Data
Price: $11.50
Daily Change: +$0.85 / 7.39%
Daily Range: $10.34 - $11.72
Market Cap: $608,888,064
Daily Volume: 308,618
Performance Metrics
1 Week: 2.23%
1 Month: 19.15%
3 Months: 9.05%
6 Months: -17.33%
1 Year: -46.77%
YTD: -17.63%
Company Details
Employees: 60
Sector: Health technology
Industry: Biotechnology
Country:
Details
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.